Savolitinib vs Vebreltinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
Reported efficacy
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)
Result source: NCT05261399
Vebreltinib
Marketed by Avistone Biotechnology under a licence from Apollomics Inc.
NCT04258033 · Phase 2 · completed
This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly.
Next expected readout: December 2026 · NCT06343064 (registry estimate)
Reported efficacy
Objective response rate (2 years): Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee (met)
Result source: NCT04258033
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Savolitinib | Vebreltinib |
|---|---|---|
| PFS, median | 8.2 vs 4.5avs chemotherapyNCT05015608 | —Trial running · NCT06970782 |
| OS, median | —Not posted · NCT04923945 | —Trial running · NCT06970782 |
| ORR | 62.1%abNCT049239451 other result
| —Trial running · NCT06970782 |
| Duration of response, median | —Not posted · NCT04923945 | —Trial running · NCT06970782 |
PFS, median
- Savolitinib
- 8.2 vs 4.5avs chemotherapyNCT05015608
- Vebreltinib
- —Trial running · NCT06970782
OS, median
- Savolitinib
- —Not posted · NCT04923945
- Vebreltinib
- —Trial running · NCT06970782
ORR
- Savolitinib
- 62.1%abNCT04923945
1 other result
- 39.2% NCT04923945
- Vebreltinib
- —Trial running · NCT06970782
Duration of response, median
- Savolitinib
- —Not posted · NCT04923945
- Vebreltinib
- —Trial running · NCT06970782
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Savolitinib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Vebreltinib's landscape